IMPORTANCE With a prevalence of 4% to 13% in the United States, autoimmune thyroiditis (AIT) is a major health problem. Besides somatic complications, patients with AIT can also experience psychiatric disorders. The extent of these organic psychiatric diseases in patients with AIT, however, is so far not commonly known.
A utoimmune thyroiditis (AIT) is a common disease with a prevalence of approximately 4% to 13% in the United States. 1, 2 It affects more women than men 1 and its frequency increases with age, up to 20% among elderly females. 3 The prevalence rates differ depending on the diagnostic criteria applied, the decade the study was conducted, and the sample examined. For example, 40% to 45% of women and 20% of men in the United Kingdom and the United States show some degree of focal thyroiditis (1 to 10 foci per cm 2 ) when examined at autopsy. 4 The terminology concerning hypothyroidism and how it can be traced back to AIT is described in eAppendix 1 and eTable 1 in the Supplement. In addition, depression and anxiety disorders are pervasive psychiatric diseases with prevalence rates of 6.6% (depression) 5, 6 and 18.1% (anxiety disorders) 6 in the United States. These numbers show that examining both AIT and depression or anxiety is of public interest. Conceivable causal associations between the thyroid metabolism and depression or anxiety disorders are described in eAppendix 1 in the Supplement. Recently, the connection between autoimmunity and psychiatric disorders has been discovered for various autoimmune diseases. N-methyl-D-aspartate receptor hypofunction caused by immunoglobulin antibodies, for instance, has been found to be associated with the development of schizophrenia and psychoses. 7, 8 Moreover, meta-analytic information suggests that tic disorders are associated with a significant increase in antistreptolysin O titers. 9 Further results indicate that autoimmune explanatory approaches are possible for bipolar disorders 10 or Alzheimer disease. 11 With the introduction of new immunologic techniques and the expansion of immunoneuropsychiatric research, evidence is accumulating that at least a subset of psychiatric disorders has an autoimmune basis. 12 Considering these insights, our analysis will contribute to a further clarification of the psychiatric associations with autoimmune thyroid disease.
There are a variety of consequences for patients with AIT. On the somatic side, hypothyroidism leads to alterations in cardiovascular function such as higher blood pressure due to increased systemic vascular resistance 13 and advanced atherosclerosis. 14 Furthermore, AIT contributes to a higher risk of infertility and early miscarriage, 15 as well as to weight gain even after treatment with thyroxine. 16 Less is known about specific psychiatric burden of symptoms in patients with AIT. Studies describe a cumulative occurrence of mood disorders and symptoms of depression among patients in a hypothyroid state, as well as frequent thyroid diseases among patients with depression. [17] [18] [19] [20] [21] Moreover, fewer studies describe symptoms of anxiety in patients with AIT. 17, [21] [22] [23] [24] Occasional investigations study other (neuro) psychological symptoms associated with AIT, such as attentional and executive disturbances, 25 fatigue, 16 or reduction in quality of life. 26, 27 Despite growing interest in the psychiatric implications of AIT, most published studies still focus on its somatic effects. A further investigation of this association has importance for public health, physicians, and patients. Societal and economic costs caused by depression and anxiety disorders are high 28, 29 and can be lowered by appropriate and early treatment. By quantitatively summarizing the results concerning AIT as a possible root of some mood disorders, the awareness for this association increases and a proper thyroid and antidepressant treatment can be implemented beyond psychotherapy. Furthermore, screening tests for symptoms of depression and anxiety in patients with AIT and for AIT in patients with depression and anxiety could be established. To our knowledge, there are only a few qualitative reviews describing an association between AIT and the development of depression and anxiety disorders, 22, [30] [31] [32] whereas no quantitative analysis concerning this topic exists. Consequently, there are no numbers of an overall association of AIT with depression and anxiety. We overcome this existing limited evidence by conducting what is, to our knowledge, the first meta-analysis testing the association of depression or anxious symptoms among individuals with AIT or any other form of hypothyroidism compared with healthy controls. We hypothesize that patients with hypothyroidism have a substantially higher risk of developing these psychiatric diseases irrespective of sex and age.
Methods

Search Strategy
German, and participants in the experimental group received a diagnosis of Hashimoto thyroiditis, AIT, or subclinical, latent, or overt hypothyroidism. The use of diverse terminology concerning AIT required a clear distinction regarding which terms to include in this meta-analysis. Hashimoto thyroiditis and autoimmune thyroiditis are used as synonyms in most of the studies even though there is a slight difference 4 between the 2 conditions (eTable 1 in the Supplement). Subclinical or latent hypothyroidism is a form of hypothyroidism in which patients have a serum thyrotropin concentration above the statistically defined upper limit of the reference range when the serum free thyroxine concentration is within its reference range. 3 Studies show that at least 50% of the individuals with serum thyrotropin levels higher than 5 mIU/L and 80% of the individuals with levels higher than 10 mIU/L have thyroid antibodies. 4 Because of these high percentages, we included subclinical or latent hypothyroidism beyond Hashimoto thyroiditis and AIT for our analysis. The American Thyroid Association additionally states that "the overwhelming majority of cases [of hypothyroidism] are due to primary thyroid gland failure because of chronic autoimmune (Hashimoto's) thyroiditis…" 34(p811) Therefore, we included samples of patients with overt hypothyroidism, as well. Additional selection criteria included a control group free from any thyroid disease and depression and anxiety disorders that were assessed via standardized instruments. Standardized instruments were defined as those with consistent questions, conditions for administering, scoring procedures, and interpretations. We included both categorical and dimensional measures; for inclusion, a study must report enough data to compute effect sizes. Data not directly reported were extracted indirectly from associated values. Exclusion criteria comprised the following: abstracts or pilot data, articles published in languages other than English or German, no quantitative assessment of depression and anxiety disorders, and articles in which the values for depression and anxiety in the experimental group were presented without a comparison with a healthy control group. It was furthermore not possible to retrieve scores from a representative norm sample to use as control group. An additional exclusion criterion was study participants comprising pregnant women. Pregnancy affects the thyroid system, leading to alterations in free triiodothyronine, free thyroxine, and thyrotropin levels 35 and could thus bias the results of our analysis. The literature search was summarized according to the PRISMA guidelines 36 (eTable 2intheSupplement).
Recorded Variables
Data extraction was performed by 2 investigators (E.-M.S. and T.W.G.) according to the previously defined coding protocol (eTable 3 in the Supplement). Disagreement was resolved by discussion and compromise on the extracted values. For the outcome variable, on the one hand we extracted the baseline sample size and the number of patients with clinically relevant scores on the depression or anxiety assessment instrument. On the other hand, we extracted the mean and SD scores on the depression or anxiety test for both groups to circumvent missing values. In the case of 2 studies, 37, 38 we used values of the representative norming sample found in the instruments' manuals 39, 40 as scores for the control group, since the original control group comprised patients with goiter. All recorded variables can be found in the coding protocol (eTable 3intheSupplement). We collected additional moderators as stated in the Statistical Analysis section. Quality was assessed via the Newcastle-Ottawa Scale for case-control studies. 41 This tool consists of 3 categories (selection, comparability, and exposure) with a total of 8 items (eTable 4 in the Supplement). A study can be awarded a maximum of 1 star for each item within the selection and exposure category and a maximum of 2 stars can be given for comparability. A higher overall quality sum score reflects superior study quality.
Statistical Analysis
The outcome measure was the odds ratio (OR) of patients with AIT and depression compared with a healthy control group, as well as the OR of patients with AIT and anxiety disorders compared with a healthy control group. The OR was calculated as the proportion of the probability to have psychiatric symptoms while being in the experimental group and the probability to have psychiatric symptoms while being in the control group. A meta-analysis was conducted using the metafor package 42 within the R open-source software environment, version 3.3.2. 43 The R code and output used in this metaanalysis are available in eAppendix 2 in the Supplement.W e performed 2 univariate meta-analyses using restricted maximum likelihood estimation in the function rma.uni(). Nonindependence among effect sizes was accounted for by aggregating. Heterogeneity among effect sizes within data sets was assessed via the I 2 statistic. This statistic can be interpreted as the percentage of the total variability in a set of effect sizes owing to between-studies variability. 44 The Cochrane handbook 44 proposes a tentative classification where I 2 of 30% to 60% indicates moderate heterogeneity, I 2 of 50% to 90% indicates substantial heterogeneity, and I 2 greater than 75% indicates considerable heterogeneity. To explain residual heterogeneity and to understand the potential effect of contextual factors on the outcome, we ran prespecified meta-regression analyses for the moderators study quality, proportion of females, and mean age. Thereby the slope of the meta-regression line (β coefficient) indicates the strength of the association between moderator and outcome. The metaregressions were Bonferroni corrected for multiple testing. We used Akaike information criteria for small sample size to indicate whether meta-regression models were more or less parsimonious than the intercept-only model.
We performed 1 prespecified subgroup analysis investigating the difference in the outcome measure between studies assessing the level of thyroid peroxidase antibodies (and thus verifying the diagnosis of AIT) and studies that did not assess the antibodies. A second post hoc subgroup analysis was conducted to examine whether dimensional measures led to different results than categorical measures.
Publication bias and small study effects were assessed with the funnel function of R, which produced contour-enhanced funnel plots for the visual detection of asymmetries. In addition, the Egger regression test for the detection of asymmetry in the funnel plot 45 was conducted. We considered analyses to be biased if the intercept differed from zero at P = .10 as the authors originally proposed. 45 We evaluated the sensitivity of our analyses by comparing fitted models with and without effect sizes that we assume to be influential outliers. Influential outliers were defined as standardized residual values exceeding 3.0 and hat values (ie, diagonal elements of the hat matrix) greater than 2 times the average hat value.
46 P < .05 (1-sided) was considered statistically significant, except for the regression test for small study effects as stated above.
Results
Database
The literature search ( Figure 1 ) identified 19 independent articles and 42 partly dependent samples since some articles contributed more than 1 sample. We identified 26 samples dealing with depression and 16 with anxiety (Table) . A total of 11 samples comprised patients with Hashimoto thyroiditis, 11 samples comprised patients with AIT, 8 samples comprised patients with subclinical hypothyroidism, and 12 samples comprised patients with overt hypothyroidism. The distinction between these 3 subtypes of hypothyroidism refers mostly to terminological differences (eAppendix 1 in the Supplement). Age, sex, instruments used to assess the psychiatric diagnosis, the country of the study population, and prevalence rates for depression and anxiety are detailed in eTable 5 in the Supplement.
Meta-analytic Association Between AIT and Depression
A total of 26 samples reported outcome data for the different forms of hypothyroidism and depression (Table) . In most of the cases, depression was assessed by self-descriptive questionnaires (eg, 10 of the samples [38.5%] ). Studies that defined psychiatric disorders via cutoff values of dimensional measures were concordant in their definitions.
We found that the chance of developing symptoms of depression that were of clinical relevance is 3.5 times higher among patients with hypothyroidism compared with healthy controls (OR, 3.56; 95% CI, 2.14-5.94) (Table) . Figure 2 shows the overall association of AIT with symptoms of depression. 17, 19, 21, 23, 25, 27, 37, 38, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Meta-analytic Association Between AIT and Anxiety Disorders A total of 16 samples reported outcome data for the different forms of hypothyroidism and anxiety disorders (Table) . Owing to a lack of data, it was not possible to detect differences among the diverse forms of anxiety disorders. Anxiety was mostly assessed via self-descriptive questionnaires (eg, 2 of the samples [12.5%] We found that the chance of developing anxiety disorders is more than 2 times higher among patients with hypothyroidism compared with healthy controls (OR, 2.32; 95% CI, 1.40-3.85) (Table) . Figure 3 shows the overall effect of AIT on anxiety disorders. 17, 21, 23, 25, 27, 37, 55, 57, [59] [60] [61] 63 Sensitivity Analysis, Publication Bias, and Meta-regression There were significant amounts of heterogeneity, both for the depression model (Q = 205.8; P < .001; I 2 = 92.1%) and the anxiety model (Q = 104.4; P < .001; I 2 = 89.8%) (Table) . Sensitivity analyses revealed no statistical outliers except for 1 study 19 touching the upper limit of the acceptable residual range (−3 to 3). Thus, the robustness of our results was confirmed. Concerning anxiety, there was no evidence of small study effects indicated by Egger regression tests. The Egger test for depression, however, revealed significant asymmetries in the distribution of published studies and thus suggests publication bias.
Slope (β), 95% CIs, and P values for meta-regression models investigating study quality, proportion of females, and mean age are detailed in eTable 6 in the Supplement. We found only 1 significant effect at a Bonferroni-corrected threshold of P = .008, indicating that the extent of symptoms of depression is moderated by the participants' mean age (β = -0.0971; P = .004). The 2 subgroup analyses revealed no significant effect on the association of AIT and depression or anxiety.
Discussion
Although underexplored, the association between AIT and depression and anxiety is an important topic with implications for both patients and physicians. Autoimmune thyroiditis is a common disease with high prevalence rates (4%-13% in the United States 1, 2 ) that increase with advancing age. 3 To ad- Gulseren et al, 27 2006
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Original ). These circumstances further amplify the relevance of our meta-analytic review.
Out of 3 moderators (study quality, proportion of females, and mean age) only mean age altered the association between AIT and depression (eTable 6 in the Supplement). Results and interpretation of the moderator analyses are discussed in eAppendix 3 of the Supplement.
Based on qualitative reviews there were strong indications of a higher prevalence of depression and anxiety among patients with hypothyroidism. Marangell and Callahan 30 describe first studies investigating a link between the thyroid gland and the brain using positron emission tomography paradigms and Hendrick and colleagues 32 point to a high occurrence of hypothyroidism among patients with therapy-resistant depression. Despite these indications, no direct association between particular alterations in brain regions because of AIT and the development of a depressive disorder was found. 18, 69 Regarding anxiety, first symptoms among patients with hypothyroidism are often generalized agitation or extreme restlessness. 22 As some of the symptoms of hypothyroidism comprise higher blood pressure 13 and sensations of nightly tachycardia, 70,71 it is presumable that this condition leads to a facilitated development of generalized anxiety disorder. Owing to a lack of data, it was not possible to test for this hypothesis in our meta-analytic review. Our results entail various implications for physicians in practice. Clinical experience shows that patients often seek medical attention owing to psychiatric symptoms but are unaware of AIT. As AIT is a chronic disease, 34 Classical, tricyclic antidepressants, however, are not suited for patients with hypothyroidism. On the one hand, patients with hypothyroidism do not respond as well to tricyclic antidepressants as patients with depression who are euthyroid 32, 68 and, on the other hand, typical adverse effects of tricyclic antidepressants such as weight gain already occur in patients with hypothyroidism 16 and can be further enhanced. It is consequently important to administer modern antidepressants with a neutral effect on weight. Moreover, patients with AIT and no symptoms of depression or anxiety must be aware of the vulnerability to develop psychiatric issues. As a consequence, both a screening for psychiatric symptoms is advisable in patients with AIT and a test for AIT is recommended in patients with depression and anxiety disorders. This test must not be narrowed down to thyrotropin levels and free triiodothyronine and free thyroxine but should comprise thyroid peroxidase antibodies as well. In populationbased studies, only 4% to 5% of patients show elevated thyrotropin levels, whereas 13% to 23% are positive for thyroid peroxidase antibodies. 1, 2, 64, 65, 79 If only the thyrotropin level is measured, a diagnostician will miss many patients with AIT detectable by assessment of thyroid peroxidase antibodies and ultrasonography. 79 As this meta-analysis clearly shows the higher prevalence of depression and anxiety in patients with hypothyroidism, it contributes to enhanced awareness and thus to faster diagnoses and appropriate treatment of patients.
Strengths and Limitations
Our analysis comprises a profound and extensive literature search, presents data of sufficient quality, and computes outcome measures independent of the studies' risk of bias. Nevertheless, there are some limitations of this study. The high levels of heterogeneity and funnel plot asymmetry for depression could result in slightly overestimated effect sizes. Furthermore, case-control studies bear the methodical risk of "superhealthy" controls and reduced generalizability owing to selection and information bias. A detailed description of strengths and limitations of our analysis can be found in eAppendix 3 in the Supplement. Future research should focus on more specific analyses, such as differentiating the various forms of hypothyroidism (eTable 1 in the Supplement) or investigating its association with subforms of anxiety. Moreover, it is important to examine the influence of AIT on concrete symptoms of depression and thus clarify the causal relationship behind this association. In a next step, the interaction of thyroid hormones and brain regions responsible for depression or anxiety should be further researched. Overall, it is necessary to develop a biopsychosocial model about the origin of depression and anxiety that also comprises AIT.
Conclusions
Autoimmune thyroiditis is associated with depression and anxiety disorders. It is thus important to enhance awareness among physicians about this connection to accelerate the diagnostic process. In patients with depression and anxiety disorders, a test for AIT should be performed and in patients with AIT, a screening for psychiatric symptoms is necessary. Advantages for patients are appropriate treatment taking into consideration early administration of antidepressants and facilitated coping owing to a better (biopsychosocial) understanding of their disease. Open Access: This article is published under the JN-OA license and is free to read on the day of publication.
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eAppendix 1. Introduction
As mentioned in the article file, there is a lack of clarity concerning the various terminology used to describe different forms of (autoimmune) thyroiditis. A lot of studies employ the terms (chronic) autoimmune thyroiditis, Hashimoto's thyroiditis and focal lymphocytic thyroiditis as synonyms. Additionally, the terms overt, subclinical and latent hypothyroidism are used in association with AIT. eTable 1 shows the different definitions and criteria used to distinguish between all these forms of hypothyroidism. Despite the diverse terminology, almost every form of hypothyroidism can be traced back to AIT: Hashimoto's thyroiditis is a variety of AIT (besides atrophic thyroiditis) and explains for most of its cases 1 . Up to 80% of subclinical and overt hypothyroidism are induced by autoimmune disorder of the thyroid gland 1 which is the most common cause of decreased thyroid hormone production in patients with acquired hypothyroidism 2 .
The pathophysiology of depression is still a matter of ongoing research. As monoaminergic drugs are effective in the treatment of depression, it has been postulated that a lack of monoamines is the underlying cause of depressive disorders 3 . Other hypotheses include a dysfunction in the hypothalamic-pituitary-adrenal regulation, causing stress and depressive symptoms 4 as well as anxiety disorders, for which monoaminergic drugs are also effective 3 . In addition, inflammatory processes have been described to be related with symptoms of major depressive disorder, especially by increasing levels of circulating pro-inflammatory cytokines 5 . AIT is an autoimmune disease in which affected persons develop antibodies against targets in the thyroid gland which has been mainly linked to genetic factors 6 . Importantly, thyroid metabolism has been shown to modulate the brain serotonin system by reducing the sensitivity of 5-HT1A autoreceptors in the Raphé area, and by increasing 5-HT2 receptor sensitivity 7 . Concerning anxiety, it is likely that the thyroid-catecholamine system interaction (via noradrenalin and T3) and its influence on sympathetic nervous system activity 8 affect symptoms such as high blood pressure 2 or sensible nightly tachycardia dat.anx$sexpr <-dat.anx$sexn/dat.anx$n1 dat.anx.help <-aggregate(dat.anx, by=list(dat.anx$sno), FUN=mean) dat.anx.agg <-agg(id=sno, es=yi, var=vi, n.1=n2, n.2=n3, cor=0.5, data=dat.anx) dat.anx.agg$study <-c(dat.anx$study [1] , dat.anx$study [2] , dat.anx$study [3] , dat.anx$study [4] , dat.anx$study [6] , dat.anx$study [7] , dat.anx$study [8] , dat.anx$study [9] , dat.anx$study [10] , dat.anx$study [13] , dat.anx$study [14] , dat.anx$study [15] , dat.anx$study [16] ) dat.anx.agg$age <-dat.anx.help$age dat.anx.agg$sexpr <-dat.anx.help$sexpr dat.anx.agg$qual1 <-dat.anx.help$qual1 dat.anx.agg$qual2 <-dat.anx.help$qual2 dat.anx.agg$qual3 <-dat.anx.help$qual3 dat.anx.agg$measure <-dat.anx.help$measure dat.anx.agg$ak <-dat.anx.help$ak ma. anx <-rma.uni(es, var, (3))) # p-values dat.depr$zi <-sign(dat.depr$yi) * qnorm(dat.depr$pval/2, lower.tail=FALSE) dat.depr$sei <-dat.depr$yi / dat.depr$zi # Confidence intervals dat.depr$sei <-replmiss(dat.depr$sei, with(dat.depr, (log(ciup) -log(cilow))/(2*1.96))) dat.depr$vi <-replmiss(dat.depr$vi, dat.depr$sei^2) # Mean and standard deviation dat.depr <-escalc(measure="D2ORN", m1i=m1_depr, sd1=sd1_depr, n1i=n2, m2i=m2_depr, sd2i=sd2_depr, n2i=n3, data=dat.depr, replace=FALSE)
# Aggregate dependent effect sizes dat.depr$sexpr <-dat.depr$sexn/dat.depr$n1 dat.depr.agg <-agg(id=sno, es=yi, var=vi, n.1=n2, n.2=n3, cor=0.5,data=dat.depr) dat.depr.help <-aggregate(dat.depr, by=list(dat.depr$sno), FUN=mean) dat.depr.agg$ak <-dat.depr.help$ak dat.depr.agg$age <-dat.depr.help$age dat.depr.agg$sexpr <-dat.depr.help$sexpr dat.depr.agg$qual1 <-dat.depr.help$qual1 dat.depr.agg$qual2 <-dat.depr.help$qual2 dat.depr.agg$qual3 <-dat.depr.help$qual3 dat.depr.agg$measure <-dat.depr.help$measure dat.depr.agg$study <-c(dat.depr$study [1] , dat.depr$study [2] , dat.depr$study [4] , dat.depr$study [5] , dat.depr$study [6] , dat.depr$study [7] , dat.depr$study [9] , dat.depr$study [12] , dat.depr$study [13] , dat.depr$study [14] , dat.depr$study [15] , dat.depr$study [16] , dat.depr$study [17] , dat.depr$study [18] , dat.depr$study [19] , dat.depr$study [22] , dat.depr$study [23] , dat.depr$study [24] , dat.depr$study [25] , dat.depr$study [26] Out of three moderators (study quality, proportion of females, mean age) only mean age altered the association between AIT and depression (For details, see eTable 6 of the supplement) on a Bonferroni corrected threshold. This result indicates that the association between AIT and depression decreases slightly when study participants show a higher averaged age. Since mean age is an aggregated variable, interpreting the moderator results as "the association of AIT and depression decreases with advancing age" must be treated with caution. Nevertheless, studies suggest that depression changes during the lifetime 11 with more age-and disease-related causal factors 12 , with elderly people being more vulnerable 11 and with a higher risk of relapse 13 . Additionally, several depression scales are loaded toward measuring somatic symptoms of depression, such as sleep disturbances or the decline of sexual function 14 . Among the elderly, these are prominent symptoms that even appear in non-depressed persons; hence, typical depression instruments overestimate the extent of depressive symptoms 14 . When applying rigorous, categorical diagnostic criteria, prevalence rates among elderly are much lower than when determining caseness by the level of depressive symptomatology 15 . Since we included both categorical and dimensional measures in our analysis, age as a moderating factor becomes plausible.
Both the other moderator variables and the subgroup analyses remained insignificant and can thus not explain for the high amount of heterogeneity (s. Table 1 ). We took into consideration post-hoc moderator analyses to reduce residual heterogeneity but due to a lack of data no further meta-regressions were conductible. Besides, there are possible explanations for the high I² statistics in our meta-analysis. First, our study sample comprises investigations from nine different countries, each varying in its baseline prevalence of depression or anxiety disorders and in its handling of psychiatric illnesses. Second, the assessment of thyroid values is not always comparable between our studies since different methods were used (e.g. immunometric assays or chemiluminescent methods for measuring TSH). Third, psychiatric diagnoses were made employing either selfdescriptive or observer-rated questionnaires. Even though most of these standardized instruments show high intercorrelations (convergent validity) they sometimes measure different aspects of one disease [16] [17] [18] [19] . Both the method for assessing TSH values and the psychiatric instruments used were prespecified moderators that could not be tested because of little group sizes. We accepted a priori the possibility of high and significant heterogeneity in order to integrate a lot of data and to provide a broad overview of the existing evidence regarding AIT and psychiatric issues.
Strengths and limitations
We retrieved data from a profound and extensive literature search (s. Figure 1 ) including more databases than usual and searching psychological platforms, as well. Furthermore, the analysis was conducted entirely following the PRISMA statement 20, 21 (eTable 2) and assessed study quality according to the Newcastle-Ottawa Quality Assessment Scale for case-control studies 22 (for details, see eTable 4 of the supplement). Three criteria, treating an adequate case definition, the definition of controls, and the application of the same method for determining exposure for both cases and controls, were fulfilled by every study we included. With a mean of 5.77 (SD = 1.17) for anxiety and a mean of 5.65 (SD = 1.14) for depression, our data are of sufficient quality. The meta-regression of study quality as a moderator remained nonsignificant (for both anxiety and depression), suggesting that our outcome measure is independent of the studies' risk of bias.
There are some limitations of this study. First, the high amount of heterogeneity could not be explained by the specified moderators. This indicates that our results show systematic variation not caused by the studies' sampling error. However, there are possible explanations for our high I² statistics, as we explained above. Second, we detected asymmetry in the funnel plot concerning depression which potentially results in slightly overestimated effect sizes. Third, the diagnosis of an AIT depends on the sample examined and the criteria applied leading to insecurities about the comparability of our studies. Though, separate analyses for every form of hypothyroidism were not possible due to little group sizes. Forth, some of the prespecified analyses (particularly subgroup analyses) could not be conducted because of insufficient data thus leaving questions unanswered. This is one further reason contributing to the high amount of heterogeneity. Fifth, there are general problems with the methodology of case-control studies themselves. With the application of this study design, several points must be considered, including the masking of raters to reduce observation bias, an appropriate definition of caseness, an adequate control group and reporting of non-response rates. Nevertheless, a recent review shows that many of the papers fail to include sufficient information to evaluate the impact of selection or information biases 23 . Hence, the generalizability of those findings is limited, and accurate replication is impeded. Another confounding influence may result from control self-selection via advertisements in which motivational factors related to personality traits or lifestyle are likely to play a role 24 . In case-control studies, the control group functions to represent the level of exposure within the general population from which the cases have been identified 23 . A typical problem for studies that assess episodes of depression and anxiety states that these diseases are somewhat common in the general population 24 . Screening out potential controls for such exposures may result in a sample of 'super-healthy' controls that would seriously inflate the case-control differences in the analysis and overestimate effect sizes 23 Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
6
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
8
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
7, 8
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
7 Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
7
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
7, Figure 1 Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
8
© 2018 American Medical Association. All rights reserved.
Section/topic # Checklist item Reported on page #
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
7, 8, eTable 3
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
9
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 9
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
8, 9, 10
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
10
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
9, 10
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Figure 1 Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
